Gilead’s TRODELVY Demonstrates Significant PFS Benefit in First-Line Metastatic TNBC in ASCENT-03 Trial
Gilead Sciences has announced positive topline results from the Phase III ASCENT-03 trial of TRODELVY (sacituzumab govitecan-hziy) in first-line metastatic triple-negative breast cancer (mTNBC) patients who are ineligible for PD-1/PD-L1 inhibitor therapies. The study met its primary endpoint by showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy. This is the first notable advance for this patient group in over two decades, underscoring TRODELVY’s potential as a new standard of care....